Q4 2024 Alembic Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Total revenue grew by 8% to INR1,517 crores for Q4 FY24.
- EBITDA increased by 29% year-over-year to INR263 crores, representing 17% of sales.
- Net profit for the quarter rose by 17% to INR178 crores.
- The US business showed significant growth with seven new product launches and a 19% increase in quarterly revenue.
- The company declared a higher dividend of INR11 per share, up from INR8 per share in the previous year.
- The India Branded business only grew by 3% in Q4, with challenges in the oral and respiratory segments.
- R&D expenses were trimmed down to INR475 crores from INR722 crores, indicating potential limitations in future innovation.
- The API business experienced pricing pressure, affecting overall margins.
- Gross margins, while strong, showed variability with a slight decline in the US business sequentially.
- The acute therapy segment in the domestic market underperformed due to a high base effect from previous years.
Ladies and gentlemen, good day, and welcome to Q4 FY24 and annual results conference call of Alembic Pharmaceuticals Limited. We have with us today Mr. Pranav Amin, Managing Director; Mr. Shaunak Amin, Managing Director; Mr. R K Baheti, Director, Finance and CFO; Mr. Ajay Kumar Desai, Senior VP, Finance; and Mr. Nilesh Wadhwa, Head International Business and Strategy.
(Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. R K Baheti. Thank you, and over to you, Mr. Baheti.
Thanks. Thank you, everyone, for joining our con call. Let me briefly take you through the numbers, financial numbers for quarter ended and year ended 31 March, 2024.
During the quarter, our total revenue grew by 8% to INR1,517 crores, EBITDA is INR263 crores, which is 17% of sales, and it grew by 29% on Y-o-Y basis. Net profit is INR178 crores grew by 17%.
During the financial year, the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
